Here You can search All About Health,Pharma,Medicine,A Thounds Articles and Medicine Pharma-Guide: Provides diverse and comprehensive data & information which can be helpful to the Pharmaceutical profession. Pharma-Guide: Provides the Country/Category wise Directory, the trade center, Bulk Drug Prices, details various exhibitions conducted from time to time worldwide. Pharma-Guide: Is a leader, promoting the industries in the global market.
Allergy to penicillin and related antibiotics
MEDICATION SAFETY ISSUES
Sound-alike/look-alike issues:
Alglucerase may be confused with agalsidase alfa, agalsidase beta, alglucosidase alfa
Ceredase® may be confused with Cerezyme®
U.S. BRAND NAMES — Ceredase®
PHARMACOLOGIC CATEGORY
Enzyme
DOSING: ADULTS — Gaucher's disease: I.V.: Initial: 30-60 units/kg every 2 weeks; dosing is individualized based on disease severity; average dose: 60 units/kg every 2 weeks. Range: 2.5 units/kg 3 times/week to 60 units/kg once weekly to every 4 weeks. Once patient response is well established, dose may be reduced every 3-6 months to determine maintenance therapy.
DOSING: PEDIATRIC — Refer to adult dosing.
DOSING: ELDERLY — Refer to adult dosing.
DOSAGE FORMS — Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Injection, solution [preservative free]:
Ceredase®: 80 units/mL (5 mL) [contains human albumin 1%]
DOSAGE FORMS: CONCISE
Injection, solution [preservative free]:
Ceredase®: 80 units/mL (5 mL)
GENERIC EQUIVALENT AVAILABLE — No
ADMINISTRATION — I.V.: Infuse I.V. over 1-2 hours. Use of an in-line filter is recommended. Do not shake solution as it denatures the enzyme.
COMPATIBILITY — Stable in NS; do not mix with any other additives.
USE — Replacement therapy for Gaucher's disease (type 1)
ADVERSE REACTIONS SIGNIFICANT — Frequency not defined.
Cardiovascular: Peripheral edema
Central nervous system: Chills, fatigue, fever, headache, lightheadedness
Endocrine & metabolic: Hot flashes, menstrual abnormalities
Gastrointestinal: Abdominal discomfort, diarrhea, nausea, oral ulcerations, vomiting
Local: Injection site: Abscess, burning, discomfort, pruritus, swelling
Neuromuscular & skeletal: Backache, weakness
Miscellaneous: Dysosmia; hypersensitivity reactions (abdominal cramping, angioedema, chest discomfort, flushing, hypotension, nausea, pruritus, respiratory symptoms, urticaria); IgG antibody formation (~13%)
CONTRAINDICATIONS — Hypersensitivity to any component of the formulation
WARNINGS / PRECAUTIONS
Concerns related to adverse effects: Hypersensitivity reactions: Patients who develop IgG antibodies may be at a higher risk for developing hypersensitivity. Use with caution in patients with prior allergies to hCG.
Disease-related concerns: Androgen-sensitive malignancies: Use with caution in patients with androgen-sensitive malignancies.
Special populations: Pediatrics: Safety and efficacy have not been established in children <2 years of age (limited experience). May cause early virilization in males <10 years of age.
Dosage form specific issues: Placental tissue: Prepared from pooled human placental tissue that may contain the causative agents of some viral diseases.
DRUG INTERACTIONS — There are no known significant interactions.
PREGNANCY RISK FACTOR — C (show table)
PREGNANCY IMPLICATIONS — Animal studies have not been conducted.
LACTATION — Excretion in breast milk unknown/use caution
MONITORING PARAMETERS — CBC, platelets, liver function tests, IgG antibody formation, acid phosphatase (AP); MRI or CT of liver and spleen, skeletal x-rays, physical exam every 6-12 months
INTERNATIONAL BRAND NAMES — Ceredase (DE, ES, GB, NL)
MECHANISM OF ACTION — Alglucerase is a modified form of glucocerebrosidase; it is prepared from human placental tissue. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide.
PHARMACODYNAMICS / KINETICS — Half-life elimination: ~3-11 minutes
Subscribe to:
Posts (Atom)
Infomed Drug Guide
The information contained in the "Infomed Drug Guide" is aimed at medical professionals and students of medicine and pharmacology. All of the data has been carefully compiled and checked, however, errors may occur. These errors may also result due to changes that have taken place in the medical sciences since the publication of the Drug Guide in 1994/2008, and cannot be excluded. In case of doubt, readers are encouraged to confirm the information contained herein with other sources before a drug is prescribed. Non-professionals should be aware that the "Infomed Drug Guide" does not seek to replace professional medical advice and/or treatment. Neither Infomed, nor the authors, claim that the information is in every respect accurate or complete. As a result, neither can be held responsible for any errors or omissions, or for any consequences resulting from the use of such information.